France· FR:68696386
LIPUR 450 mg, comprimé pelliculé
A gemfibrozil product containing gemfibrozil, registered in France by PFIZER HOLDING FRANCE, on the national reimbursement list. The same ATC class is registered in 12 of our 19 countries.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
Where it is registered
Gemfibrozil is registered in 12 of 19 countries.
Countries holding a registration under ATC C10AB04 (gemfibrozil), each read from that country’s own register.
- This record: France, from Base de données publique des médicaments — BDPM (France)
- 6 of them publish a price we can compare per daily dose
Gemfibrozil · ATC C10AB04
12 / 19 countries
- Canada
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of gemfibrozil costs, country by country.
Normalised to the WHO defined daily dose (1.2 g), so markets compare like for like.
- France: $0.50 per daily dose (median across products in the class)
- Public list prices, converted to USD at the rate date shown
Gemfibrozil · price per daily dose (1.2 g)
USD · FX 28 Sept 2026
- FR France$0.50
- IT Italy$0.42
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- GEMFIBROZIL
- Manufacturer
- PFIZER HOLDING FRANCE
- Country
- France (FR)
- ATC code
- C10AB04
- ATC class
- Gemfibrozil
- Defined daily dose
- 1.2 g, O
- Reimbursed
- Yes
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- cip133400932606351plaquette(s) PVC aluminium de 60 comprimé(s)EUR 9.86
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
165 interactions on record for gemfibrozil.
Graded by severity as the source publishes them — 19 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Gemfibrozil · interactions on record
165 records
- 19 severe
- 57 moderate
- 2 minor
- 85 info
Most severe, free to view
- LoperamideA07DA03severe
- EluxadolineA07DA06severe
- PioglitazoneA10BG03severe
- RepaglinideA10BX02severe
2 more interactions with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Gemfibrozil in 11 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- NetherlandsLopid 450 mg, filmomhulde tablettenPfizer B.V.
- United StatesGemfibrozilREMEDYREPACK INC.
- United KingdomGemfibrozil 300mg capsulesA A H Pharmaceuticals Ltd
- SpainGEMFIBROZILO STADA 600 mg COMPRIMIDOS EFGLaboratorio Stada S.L.
- ItalyGEMFIBROZIL DOC GENERICIDOC GENERICI S.R.L.
- FinlandGevilonOrion Corporation Orion Pharma
- IrelandLopid 300 mg capsules, hardPfizer Healthcare Ireland Unlimited Company
- NorwayLopidPfizer
Authorised across Europe · EMA
The same active substance is authorised in 11 EEA countries. Names it is sold under:
- Austria · Gevilon
- Cyprus · Ipolipid, Lipofor
- Denmark · Lopid
- Spain · Gemfibrozilo Stada, Gemfibrozilo Tarbis
- United Kingdom (Northern Ireland) · Gemfibrozil Tillomed Laboratories, Lopid
- Greece · Fibrolip, Gemlipid
- Ireland · Lopid
- Iceland · Lopid
- Italy · Gemfibrozil Doc Generici, Gemfibrozil Eg
- Netherlands · Gemfibrozil Aurobindo, Lopid
- Portugal · Gemfibrozil Generis, Lopid
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/4dfbc950-2f42-4fd1-9c99-def62af7272f GET /v1/drugs/4dfbc950-2f42-4fd1-9c99-def62af7272f?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "68696386",
"date_amm": "1982-07-21",
"type_amm": "Procédure de reconnaissance mutuelle",
"numero_ue": null,
"substance": "GEMFIBROZIL",
"atc_source": "fr_atc_restore_2026-09-06",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "comprimé pelliculé",
"voies_administration": "orale",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Non"
}See everything about gemfibrozil.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.